Partner
Yieyie has handled various aspects of trial preparation, including fact and expert discovery, depositions of key witnesses and experts, and motion practice, along with other pre-litigation due diligence and position analysis. She also has worked on multiple IPR cases on behalf of petitioners or patent owners and has been involved in all aspects of those cases, including developing key arguments, preparing and sitting in expert depositions, drafting expert declarations and key papers, and preparing for oral arguments. In addition, Yieyie has conducted a variety of due diligence analysis in the biotechnological field for licensing, acquisition, freedom-to-operate, and startup fundraising.
Yieyie's scientific background is in molecular and cancer biology. Her graduate research focused on identifying novel genes involved in axon guidance during the development of the nervous system, and her new findings were published in peer-reviewed scientific journals. During her post-doctoral research period at the Dana-Farber Cancer Institute, she studied epigenetic chromatin-remodeling complexes and identified tumor suppressor candidates that interact with oncogenes during cellular transformation and tumorigenesis.
While in law school, Yieyie also paid close attention to the development of Chinese intellectual property law. Her articles on Chinese patent law have been published by peer-reviewed law journals.
Grünenthal GmbH et al. v. Actavis Elizabeth LLC et al.
Member of team that represented Grünenthal GmbH in multiple Hatch-Waxman suits involving analgesic drugs Nucynta® and Nucynta® ER; the district court enjoined the defendants from marketing generic versions until patent expiry.
2:13-cv-04507, -06929, -07803; 2:14-cv-03941, -04617; 2:15-cv-06797, D.N.J., Judges Cecchi, Falk
Eli Lilly and Company v. Actavis Labs. UT Inc.
Member of team representing Eli Lilly in Hatch-Waxman action against several defendants relating to Cialis®.
1:16-cv-01119, E.D. Va., Judges Nachmanoff, Trenga
Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Member of team representing Eli Lilly in an appeal from a Patent Trial and Appeal Board (PTAB) decision in an IPR case.
IPR2014-00693, -00752, PTAB, Judges Green, Prats, Snedden
16-1547, Fed. Cir., Judges Bryson, Moore, Newman
AstraZeneca LP v. SigmaPharm Laboratories
Member of team representing AstraZeneca in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.
1:15-cv-01000, D. Del., Judge Andrews
Actelion Pharmaceuticals v. ICOS Corp.
Member of team representing ICOS in two IPRs defending their formulation patents.
IPR2015-00561, -00562, PTAB, Judges Mitchell, Snedden, Yang
Eli Lilly and Company v. Teva Pharmaceuticals International
Member of team representing Eli Lilly in multiple IPRs involving antibody patents.
IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Event
Biosimilars and Interchangeable Biologics: New FDA Draft Guidance Clarifying Application Process for Approval Biosimilars and Interchangeable Biologics: New FDA Draft Guidance Clarifying Application Process for Approval
November 28, 2023
Webinar
Event
Secondary Patents on Both Sides of the Pond: Impact of Clinical Trials on Patentability Secondary Patents on Both Sides of the Pond: Impact of Clinical Trials on Patentability
November 2, 2023
Webinar
Event
Patent Drafting for Multiple Jurisdictions Patent Drafting for Multiple Jurisdictions
October 11, 2023
Webinar
Commentary
Fed. Circ. OKs Boston Drug Developer's Patent Win Fed. Circ. OKs Boston Drug Developer's Patent Win
March 11, 2024
Law360Press Release
Finnegan Announces 2024 Partner Class Finnegan Announces 2024 Partner Class
January 2, 2024
Press Release
32 Finnegan Attorneys Recognized by Best Lawyers 32 Finnegan Attorneys Recognized by Best Lawyers
August 17, 2023
Best LawyersPress Release
ITC Determines Healthgen’s Medium Grade Products Did Not Infringe Ventria’s Patent ITC Determines Healthgen’s Medium Grade Products Did Not Infringe Ventria’s Patent
September 16, 2022
Press Release
29 Finnegan Attorneys Ranked by Best Lawyers 29 Finnegan Attorneys Ranked by Best Lawyers
August 18, 2022
U.S. News—Best LawyersDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.